文献速递临床试验与 GCP基础与转化研究

在塞拉利昂健康成人中评估重组5型腺病毒载体埃博拉疫苗的安全性和免疫原性:一项单中心、随机、双盲、安慰剂对照的2期试验

Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet · 2016-12-23

在塞拉利昂弗里敦单中心开展随机双盲安慰剂对照2期试验,500名健康成人按2:1:1分配至高剂量疫苗组(250例)、低剂量疫苗组(125例)或安慰剂组(125例)。接种后7天内征集性不良事件发生率分别为高剂量组53%、低剂量组48%、安慰剂组43%;注射部位不良事件疫苗组高于安慰剂组。糖蛋白特异性抗体反应自第14天检出、第28天达峰,随后数月快速下降。作者认为该疫苗安全且免疫原性强,8.0×10^10病毒颗粒为最佳剂量。

要点

  • 高剂量组132例(53%)、低剂量组60例(48%)、安慰剂组54例(43%)报告至少1项征集性不良事件。
  • 注射部位征集性不良事件:高剂量组65例(26%)、低剂量组31例(25%)vs 安慰剂组17例(14%),p=0.0169。
  • 糖蛋白特异性抗体几何平均滴度第28天达峰:低剂量组1471.8(95%CI 1151.0-1881.8)、高剂量组2043.1(1762.4-2368.4)。

核心结论

  • 作者认为该重组5型腺病毒载体埃博拉疫苗在健康塞拉利昂成人中安全且免疫原性强,8.0×10^10病毒颗粒为最佳剂量。

研究设计与样本

  • 在塞拉利昂弗里敦塞拉利昂-中国友谊医院开展单中心、随机、双盲、安慰剂对照2期临床试验。
  • 招募18-50岁HIV阴性、无埃博拉病毒感染史且未接种过其他埃博拉候选疫苗的健康成人。
  • 2015年10月10日至28日共入组500名参与者,按2:1:1随机分配至高剂量疫苗组(n=250)、低剂量疫苗组(n=125)或安慰剂组(n=125)。
  • 高剂量为1.6×10^11病毒颗粒,低剂量为8.0×10^10病毒颗粒,安慰剂仅含疫苗辅料、无病毒颗粒。
  • 主要安全性结局为接种后7天内征集性不良反应发生情况,按意向性分析;主要免疫原性结局为接种后第14、28、168天糖蛋白特异性抗体反应,在所有采集血样进行抗体检测的接种者中分析。

主要发现

  • 接种后7天内至少报告1项征集性不良事件:高剂量组132例(53%)、低剂量组60例(48%)、安慰剂组54例(43%),多数不良事件为轻度和自限性。
  • 注射部位征集性不良事件:高剂量组65例(26%)、低剂量组31例(25%)vs 安慰剂组17例(14%),p=0.0169。
  • 糖蛋白特异性抗体反应自第14天检出,几何平均滴度低剂量组1251.0(95%CI 976.6-1602.5)、高剂量组1728.4(1459.4-2047.0)。
  • 抗体几何平均滴度第28天达峰,低剂量组1471.8(95%CI 1151.0-1881.8)、高剂量组2043.1(1762.4-2368.4)。
  • 抗体几何平均滴度第168天下降至低剂量组223.3(95%CI 148.2-336.4)、高剂量组254.2(185.0-349.5);安慰剂组在整个研究期间维持在约6.0-6.8。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A recombinant adenovirus type-5 vector-based vaccine expressing the glycoprotein of Ebola Zaire Makona variant showed good safety and immunogenicity in a phase 1 trial of healthy Chinese adults. We aimed to assess the safety and immunogenicity of this vaccine in healthy adults in Sierra Leone and to determine the optimal dose. METHODS: We did a single-centre, randomised, double-blind, placebo-controlled, phase 2 clinical trial at Sierra Leone-China Friendship Hospital, Freetown, Sierra Leone. We recruited healthy adults aged 18-50 years who were HIV negative, had no history of Ebola virus infection, and had no previous immunisation with other Ebola vaccine candidates. Participants were sequentially enrolled and randomly assigned (2:1:1), by computer-generated block randomisation (block size of eight), to receive the high-dose vaccine (1·6 × 1011 viral particles), low-dose vaccine (8·0 × 1010 viral particles), or placebo (containing only vaccine excipients, with no viral particles). Participants, investigators, and study staff (except two study pharmacists) were masked from treatment allocation. The primary safety outcome was occurrence of solicited adverse reactions within 7 days of vaccination, analysed by intention to treat. The primary immunogenicity outcome was glycoprotein-specific antibody responses at days 14, 28, and 168 after vaccination, analysed in all vaccinated participants who had blood samples drawn for antibody tests. The trial is registered with the Pan African Clinical Trials Registry, number PACTR201509001259869, and is completed. FINDINGS: During Oct 10-28, 2015, 500 participants were enrolled and randomly assigned to receive the high-dose vaccine (n=250), low-dose vaccine (n=125), or placebo (n=125). 132 (53%) participants in the high-dose group, 60 (48%) in the low-dose group, and 54 (43%) in the placebo group reported at least one solicited adverse reaction within 7 days of vaccination. Most adverse reactions were mild and self-limiting. Solicited injection-site adverse reactions were significantly more frequent in vaccine recipients (65 [26%] in high-dose group and 31 [25%] in low-dose group) than in those receiving placebo (17 [14%]; p=0·0169). Glycoprotein-specific antibody responses were detected from day 14 onwards (geometric mean titre 1251·0 [95% CI 976·6-1602·5] in low-dose group and 1728·4 [1459·4-2047·0] in high-dose group) and peaked at day 28 (1471·8 [1151·0-1881·8] and 2043·1 [1762·4-2368·4]), but declined quickly in the following months (223·3 [148·2-336·4] and 254·2 [185·0-349·5] at day 168). Geometric mean titres in the placebo group remained around 6·0-6·8 throughout the study period. Three serious adverse events (malaria, gastroenteritis, and one fatal asthma episode) were reported in the high-dose vaccine group, but none was deemed related to the vaccine. INTERPRETATION: The recombinant adenovirus type-5 vector-based Ebola vaccine was safe and highly immunogenic in healthy Sierra Leonean adults, and 8·0 × 1010 viral particles was the optimal dose. FUNDING: Chinese Ministry of Science and Technology and the National Health and Family Planning Commission, Beijing Institute of Biotechnology, and Tianjin CanSino Biotechnology.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Zhu FC, Wurie AH, Hou LH, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2016. PMID: 28017399. doi:10.1016/S0140-6736(16)32617-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。